Search results
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 1 day agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 1 day agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 1 day agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company ...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 1 day agoA Food and Drug Administration decision on approval of Moderna’s RSV vaccine is expected by May 12,...
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 day agoThe 10 stocks that made the cut could produce...Stock Advisor returns as of April 30, 2024 Stéphane Bancel -- Chief Executive Officer Thank...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 14 hours agoModerna Inc (NASDAQ:MRNA) reported a net loss of $1.2...in the regulatory and competitive landscape, particularly with the upcoming need for vaccine approvals ...
Earnings call: Moderna reports a net loss of $12.2 billion By Investing.com
Investing.com· 1 day agoThe biotechnology company, known for its mRNA vaccine technology, highlighted its strategic...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 1 day agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its ...
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline
Guru Focus· 2 days agoOn May 2, 2024, Moderna Inc (MRNA, Financial) released its 8-K filing, disclosing a challenging first quarter with total revenues of $167 million, a stark decline from $1.9 ...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 1 day agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.